Fatal hepatotoxicity due to sevoflurane use in a paediatric patient after aortic repair: reality or fiction? A case of pharmacovigilance.
Llefer V SanchezPol PichardoVicky AdamesAndrea ZoviNicola PradeganPublished in: European journal of hospital pharmacy : science and practice (2021)
Hepatotoxicity secondary to exposure of volatile anaesthetics is an exceptional finding, but its clinical interest depends on their frequent use, unpredictable appearance and potential severity. Halothane is the volatile anaesthetic most frequently involved in the development of liver dysfunction, especially after re-exposure. Sevoflurane has rarely been related to this life-threatening complication. We present the case of a 1-year-old girl who had undergone previous surgery for closure of a patent ductus arteriosus, and who developed severe acute hepatitis and died after undergoing surgical repair of an aortic isthmus narrowing by means of general anaesthesia with sevoflurane. Other possible causes of liver failure were excluded. This adverse event was classified as serious and was included in the national and European pharmacovigilance network, with the aim of preventing dangerous effects on patient health in clinical practice, by contributing to the enrichment of the literature.
Keyphrases
- drug induced
- liver failure
- adverse drug
- clinical practice
- case report
- aortic valve
- hepatitis b virus
- public health
- healthcare
- minimally invasive
- systematic review
- left ventricular
- emergency department
- pulmonary artery
- intensive care unit
- oxidative stress
- coronary artery bypass
- gas chromatography
- aortic dissection
- quality improvement
- acute coronary syndrome
- high resolution
- coronary artery disease
- pulmonary arterial hypertension
- social media
- surgical site infection
- percutaneous coronary intervention